Pro PG receives S19A approval for Gemfibrozil Tablets USP 600mg (Cipla USA)

Historical supply notice: This article relates to a previous medicine shortage or regulatory approval. Availability and regulatory status may have changed. Healthcare professionals should contact Pro Pharmaceuticals Group to confirm the current supply position.

For current Australian shortage and supply information, see medicine shortages in Australia.

Pro Pharmaceuticals Group has arranged for the supply of the following overseas registered Gemfibrozil products on a temporary basis:

Gemfibrozil Tablets USP 600mg (Cipla USA)

This products are NOT registered in Australia and supply is authorised under an exemption granted by the Therapeutic Goods Administration (TGA) under section 19A of the Therapeutic Goods Act 1989 until 31st July 2022.

Please contact us for more information.

Link to Dear Health Care Professional Label